Aptevo Therapeutics annual free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
Aptevo Therapeutics Free Cash Flow (FCF) History (APVO)
Aptevo Therapeutics reported −$21.1M in free cash flow for fiscal 2022, an increase of $1.3M from the previous fiscal year, with a free cash flow margin of −676.01%.
View full Aptevo Therapeutics company overviewAptevo Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$21.1M | $1.3M | — | −676.01% |
| 2021 | 2021-12-31 | −$22.4M | $7.0M | — | −182.17% |
| 2020 | 2020-12-31 | −$29.4M | $13.1M | — | −682.43% |
| 2019 | 2019-12-31 | −$42.5M | $9.9M | — | −131.19% |
| 2018 | 2018-12-31 | −$52.4M | −$9.4M | — | −227.16% |
| 2017 | 2017-12-31 | −$43.0M | −$3.6M | — | −293.18% |
| 2016 | 2016-12-31 | −$39.4M | $10.9M | — | −394.33% |
| 2015 | 2015-12-31 | −$50.3M | — | — | −149.66% |
Aptevo Therapeutics quarterly free cash flow
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q3.22
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2022 | 2022-09-30 | −$6.9M | $795,000 | — | — |
| Q4 2021 | 2021-12-31 | −$4.0M | $1.1M | — | −109.09% |
| Q3 2021 | 2021-09-30 | −$5.3M | $2.3M | — | −169.74% |
| Q2 2021 | 2021-06-30 | −$5.4M | $10.4M | — | −175.05% |
| Q1 2021 | 2021-03-31 | −$7.7M | $6.3M | — | −317.84% |
| Q4 2019 | 2019-12-31 | −$5.1M | $2.2M | — | −56.47% |
| Q3 2019 | 2019-09-30 | −$7.5M | $4.0M | — | −83.76% |
| Q2 2019 | 2019-06-30 | −$15.9M | $209,000 | — | −215.91% |
| Q1 2019 | 2019-03-31 | −$14.0M | $3.5M | — | −199.33% |
| Q4 2018 | 2018-12-31 | −$7.3M | $8.4M | — | −115.68% |
| Q3 2018 | 2018-09-30 | −$11.5M | −$9.8M | — | −197.56% |
| Q2 2018 | 2018-06-30 | −$16.1M | −$3.4M | — | −235.86% |
| Q1 2018 | 2018-03-31 | −$17.5M | −$4.6M | — | −428.67% |
| Q4 2017 | 2017-12-31 | −$15.7M | −$8.5M | — | −557.70% |
| Q3 2017 | 2017-09-30 | −$1.8M | −$1.6M | — | −28.37% |
| Q2 2017 | 2017-06-30 | −$12.7M | $4.2M | — | −359.81% |
| Q1 2017 | 2017-03-31 | −$12.8M | $2.4M | — | −598.55% |
| Q4 2016 | 2016-12-31 | −$7.2M | $2.5M | — | — |
| Q3 2016 | 2016-09-30 | −$180,000 | — | — | −6.39% |
| Q2 2016 | 2016-06-30 | −$16.9M | — | — | −165.40% |
| Q1 2016 | 2016-03-31 | −$15.2M | — | — | −188.21% |
| Q3 2015 | 2015-09-30 | −$9.8M | — | — | −149.24% |
Aptevo Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$43.0M to −$21.1M, a net increase of $21.9M. Aptevo Therapeutics's latest reported quarter, Q3 2022, generated −$6.9M in free cash flow, an increase of $795,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Aptevo Therapeutics filings at SEC.gov ↗